- Home
- BRKL vs QURE Comparison
BRKL vs QURE Comparison
Compare BRKL & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKL
- QURE
- Stock Information
- Founded
- BRKL 1871
- QURE 1998
- Country
- BRKL United States
- QURE Netherlands
- Employees
- BRKL N/A
- QURE N/A
- Industry
- BRKL Savings Institutions
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- BRKL Finance
- QURE Health Care
- Exchange
- BRKL Nasdaq
- QURE Nasdaq
- Market Cap
- BRKL 897.3M
- QURE 725.4M
- IPO Year
- BRKL 1998
- QURE 2007
- Fundamental
- Price
- BRKL $10.34
- QURE $14.33
- Analyst Decision
- BRKL Buy
- QURE Strong Buy
- Analyst Count
- BRKL 2
- QURE 10
- Target Price
- BRKL $15.25
- QURE $37.20
- AVG Volume (30 Days)
- BRKL 537.3K
- QURE 1.3M
- Earning Date
- BRKL 07-23-2025
- QURE 07-31-2025
- Dividend Yield
- BRKL 5.20%
- QURE N/A
- EPS Growth
- BRKL N/A
- QURE N/A
- EPS
- BRKL 0.82
- QURE N/A
- Revenue
- BRKL $338,567,000.00
- QURE $20,201,000.00
- Revenue This Year
- BRKL $53.95
- QURE N/A
- Revenue Next Year
- BRKL $68.33
- QURE $278.91
- P/E Ratio
- BRKL $12.67
- QURE N/A
- Revenue Growth
- BRKL N/A
- QURE 6.30
- 52 Week Low
- BRKL $8.15
- QURE $3.73
- 52 Week High
- BRKL $13.15
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- BRKL 48.53
- QURE 46.16
- Support Level
- BRKL $9.98
- QURE $13.65
- Resistance Level
- BRKL $10.61
- QURE $15.35
- Average True Range (ATR)
- BRKL 0.21
- QURE 1.00
- MACD
- BRKL 0.00
- QURE -0.30
- Stochastic Oscillator
- BRKL 46.75
- QURE 17.22
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.